Company intelligence / Profile preview

t2cure

Frankfurt am Main, Hesse, Germany

Ownership: Private
Development stage: Other

Overview

t2c001, an autologous cellular therapeutic derived from patients' own bone marrow, received orphan drug designation for Buerger’s Disease and has shown promising clinical benefits in pilot studies. The product has successfully passed Phase II and is commercially available in Germany for patients with myocardial infarction.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyStem cell therapyAutologous cell therapy
Industry: Biotech

Drug pipeline

1 asset

T2C001-AMI

Unknown

Partnerships

Johann Wolfgang Goethe-Universität Frankfurt am Main (originator for some programs)

Beyond the preview

Go deeper on t2cure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on t2cure.

Explore the full profile